KIR3DL2 Binding Antibodies Resolving Internalization and Affinity Trade-offs
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibodies targeting KIR3DL2 are either of the IgM isotype, not suitable for pharmaceutical use, have low affinity when converted to IgG, and internalize upon binding, hindering ADCC-based approaches, while also lacking specificity for human KIR3DL2 over closely related receptors.
Innovation Solution
Development of monoclonal antibodies that selectively bind human KIR3DL2 without internalizing, increasing cell surface KIR3DL2 expression, and blocking KIR3DL2-HLA B27 interactions without affecting KIR3DL2-HLA A3 interactions, with broad allele specificity to treat malignancies and autoimmune disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current antibodies targeting KIR3DL2 are used, then binding to KIR3DL2 is achieved, but the antibodies internalize upon binding which hinders ADCC-based approaches
Solution Approach 1:
The patent applies parameter changes by modifying the antibody structure (changing from IgM to IgG isotype, engineering specific variable regions) to alter the binding characteristics. This resolves the contradiction by maintaining reliable binding while changing the internalization parameter to a non-internalizing state, enabling ADCC-based therapeutic approaches.
2Ease of manufacture
If current antibodies are converted to IgG isotype, then pharmaceutical suitability is improved, but binding affinity decreases
Solution Approach 1:
The patent resolves this contradiction through parameter changes in the antibody variable regions. By engineering specific CDR sequences and variable region structures, the patent achieves both IgG isotype compatibility (pharmaceutical suitability) and high binding affinity to KIR3DL2, eliminating the trade-off between manufacturability and binding strength.
3Reliability
If antibodies are designed to bind KIR3DL2, then therapeutic effect is achieved, but specificity over closely related receptors (KIR3DL1, KIR3DS1) is not maintained
Solution Approach 1:
The patent applies local quality by designing the antibody variable regions to recognize specific local epitopes on KIR3DL2 that are distinct from KIR3DL1 and KIR3DS1. This localized specificity in the binding region allows the antibody to achieve therapeutic effects on KIR3DL2-expressing cells while maintaining selectivity and avoiding off-target binding to related receptors.
4Reliability
If IgM isotype antibodies are used, then binding to KIR3DL2 is achieved, but they are not suitable for pharmaceutical use
Solution Approach 1:
The patent resolves this contradiction by changing the isotype parameter from IgM to IgG. This parameter change maintains the binding capability to KIR3DL2 while conferring pharmaceutical suitability through the IgG isotype's favorable pharmacokinetic properties, stability, and compatibility with standard pharmaceutical manufacturing and administration protocols.
Data Source
AI summary
The present invention relates to methods for the treatment of cancer and inflammatory disease using antibodies (e.g. monoclonal antibodies), antibody fragments, and derivatives thereof that specifically bind KIR3DL2. The invention also relates to antibodies, cells producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; pharmaceutical compositions comprising the same.